Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
To determine whether medical reduction of intraocular pressure prevents or delays the onset
of glaucomatous visual field loss and/or optic disc damage in ocular hypertensive
participants judged to be at moderate risk for developing open-angle glaucoma.
To produce natural history data to assist in identifying patients at most risk for developing
open-angle glaucoma and those most likely to benefit from early medical treatment.
To quantify risk factors for developing open-angle glaucoma among ocular hypertensive
individuals.
Phase
Phase 3
Funding Agency/Sponsor
Other
Disease
Glaucoma
Enrollment Eligibility
Men and nonpregnant women between the ages of 40 and 80 with IOP greater than or equal to
24 mm Hg but less than or equal to 32 mm Hg in at least one eye and IOP greater than or
equal to 21 but less than or equal to 32 mm Hg in the fellow eye, as well as normal visual
fields and optic discs are eligible for the trial. Patients presenting with best-corrected
visual acuity worse than 20/40 in either eye, previous intraocular surgery, a
life-threatening or debilitating disease, secondary causes of elevated IOP, angle-closure
glaucoma or anatomically narrow angles, other diseases that can cause visual field loss,
background diabetic retinopathy, optic disc abnormalities that can produce visual field
loss or obscure the interpretation of the optic disc, or unwillingness to undergo random
assignment are excluded from the trial.